Aurora Cannabis Inc. announced on April 28 2026 that it will broaden its global medical cannabis portfolio with the launch of dried flower, pre‑rolls and pastilles in Canada, Europe and Australia. The new formats will be available in Germany, Poland, Australia and Canada, with a rollout scheduled to begin immediately and complete by June 2026.
The company will leverage its 90 % GMP‑certified manufacturing capacity to supply the new products. Aurora’s EU‑GMP certified facilities in Canada and Germany, along with the recently acquired Safari Flower Company, provide the cultivation and processing capacity needed to meet the expanded demand in these key markets.
Aurora’s Q1 fiscal 2026 results showed a 17 % increase in net revenue to $98 million, with global medical cannabis revenue up 37 % and international revenue up 85 %. The company also posted positive free cash flow of $9.2 million and adjusted EBITDA of $10.8 million, underscoring the financial momentum that supports the new product launches.
The launches are designed to address specific market needs. Germany will receive a broader portfolio of medical cannabis options, Poland will see an expanded potency range, Australia will launch discreet, precisely dosed pastilles, and Canada will grow its core medical offerings. By offering dried flower, pre‑rolls and pastilles, Aurora aims to meet prescriber and patient demand for diverse, reliable medical cannabis options while maintaining regulatory compliance.
Lana Culley, Vice President of Innovation & International Operations, said, "By expanding our offerings in key countries, we’re responding to clear patient and prescriber demand with products that meet local regulatory standards."
The product launches reinforce Aurora’s medical‑first strategy, which has shifted the company away from the recreational segment toward higher‑margin medical markets. The acquisition of Safari Flower Company on April 15 2026, and the expansion of EU‑GMP certified cultivation capacity, further strengthen Aurora’s ability to supply regulated international markets and support the company’s long‑term growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.